BRPI0915770A2 - composição de modulação de apoptose de liberação controlada e métodos para o tratamento de distúrbios ótológicos - Google Patents

composição de modulação de apoptose de liberação controlada e métodos para o tratamento de distúrbios ótológicos

Info

Publication number
BRPI0915770A2
BRPI0915770A2 BRPI0915770A BRPI0915770A BRPI0915770A2 BR PI0915770 A2 BRPI0915770 A2 BR PI0915770A2 BR PI0915770 A BRPI0915770 A BR PI0915770A BR PI0915770 A BRPI0915770 A BR PI0915770A BR PI0915770 A2 BRPI0915770 A2 BR PI0915770A2
Authority
BR
Brazil
Prior art keywords
disorders
optimal
treating
methods
controlled release
Prior art date
Application number
BRPI0915770A
Other languages
English (en)
Inventor
Andrew M Trammel
Benedikt Vollrath
Carl Lebel
Fabrice Piu
Jeffrey P Harris
Jay Lichter
Luis A Dellamary
Michael Christopher Scaife
Qiang Ye
Sergio G Durón
Original Assignee
Otonomy Inc
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0907065A external-priority patent/GB2461961A/en
Application filed by Otonomy Inc, Univ California filed Critical Otonomy Inc
Publication of BRPI0915770A2 publication Critical patent/BRPI0915770A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
BRPI0915770A 2008-07-14 2009-07-09 composição de modulação de apoptose de liberação controlada e métodos para o tratamento de distúrbios ótológicos BRPI0915770A2 (pt)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US8058308P 2008-07-14 2008-07-14
US8245008P 2008-07-21 2008-07-21
US9438408P 2008-09-04 2008-09-04
US10111208P 2008-09-29 2008-09-29
US11051108P 2008-10-31 2008-10-31
US14003308P 2008-12-22 2008-12-22
US16484109P 2009-03-30 2009-03-30
GB0907065A GB2461961A (en) 2008-07-14 2009-04-24 Sterile anti-apoptotic agent for treatment of ear diseases
PCT/US2009/050077 WO2010008995A2 (en) 2008-07-14 2009-07-09 Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders

Publications (1)

Publication Number Publication Date
BRPI0915770A2 true BRPI0915770A2 (pt) 2015-11-03

Family

ID=41530817

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0915770A BRPI0915770A2 (pt) 2008-07-14 2009-07-09 composição de modulação de apoptose de liberação controlada e métodos para o tratamento de distúrbios ótológicos

Country Status (13)

Country Link
US (3) US20100016218A1 (pt)
EP (1) EP2296632A4 (pt)
JP (1) JP5491502B2 (pt)
KR (1) KR101390607B1 (pt)
CN (1) CN102099013A (pt)
AU (1) AU2009271129B2 (pt)
BR (1) BRPI0915770A2 (pt)
CA (1) CA2730847A1 (pt)
IL (2) IL210553A0 (pt)
MX (1) MX2011000545A (pt)
RU (1) RU2493828C2 (pt)
WO (1) WO2010008995A2 (pt)
ZA (1) ZA201008861B (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8604042B2 (en) * 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
DK1951684T3 (en) * 2005-11-01 2016-10-24 Targegen Inc BIARYLMETAPYRIMIDIN kinase inhibitors
US8133900B2 (en) * 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
WO2009132050A2 (en) 2008-04-21 2009-10-29 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
US8030297B2 (en) 2008-05-14 2011-10-04 Otonomy, Inc. Controlled release corticosteroid compositions and methods for the treatment of OTIC disorders
US8846770B2 (en) 2008-06-18 2014-09-30 Otonomy, Inc. Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders
WO2010011466A2 (en) 2008-06-27 2010-01-28 Otonomy, Inc. Controlled-release cns modulating compositions and methods for the treatment of otic disorders
US8496957B2 (en) 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US8784870B2 (en) 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
EP2344151A4 (en) 2008-10-22 2012-04-18 House Ear Inst THERAPEUTIC AND / OR PROPHYLACTIC TREATMENT OF INTERNAL EAR PATHOLOGIES BY MODULATION OF THE METABOTROPIC GLUTAMATE RECEPTOR
WO2012060847A1 (en) * 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
EP2675409A4 (en) * 2011-02-18 2015-04-08 Otonomy Inc PREVENTION OF MEDICATION-INDUCED OTOTOXICITY AND RECOVERY AFTER MEDICATION-INDUCED OTOTOXICITY
WO2012122025A2 (en) 2011-03-04 2012-09-13 Intrexon Corporation Vectors conditionally expressing protein
US20140189897A1 (en) 2011-06-21 2014-07-03 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
JP6170047B2 (ja) 2011-08-31 2017-07-26 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド アポトーシス−ターゲティングナノ粒子
WO2013090645A1 (en) 2011-12-13 2013-06-20 Buck Institute For Research On Aging Methods for improving medical therapies
US10416167B2 (en) 2012-02-17 2019-09-17 University Of Georgia Research Foundation, Inc. Nanoparticles for mitochondrial trafficking of agents
WO2013158664A2 (en) 2012-04-17 2013-10-24 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
US9901081B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse for determining the role of senescent cells in cancer
US9901080B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
US10279018B2 (en) 2012-12-03 2019-05-07 Unity Biotechnology, Inc. Immunogenic compositions for inducing an immune response for elimination of senescent cells
RU2528917C1 (ru) * 2013-07-29 2014-09-20 государственное бюджетное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации Фармакологическая композиция с антибактериальными свойствами для лечения наружных отитов
WO2015031393A1 (en) 2013-08-27 2015-03-05 Otonomy, Inc. Treatment of pediatric otic disorders
US10634677B2 (en) * 2013-10-14 2020-04-28 Indiana University Research And Technology Corporation Use of acamprosate to modulate ERK1/2 activation in animal models for FXS and ASD and individuals diagnosed with FXS and ASD
RU2707748C2 (ru) 2013-11-08 2019-11-29 Активус Фарма Ко., Лтд. Композиция водной суспензии, включающая наночастицы макролидных антибиотиков
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
MX2016009753A (es) 2014-01-28 2017-07-07 Buck Inst For Res On Aging Metodos y composiciones para exterminar celulas senescentes y para tratar enfermedades y trastornos asociados con la senectud.
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
US20170216286A1 (en) * 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
US10398663B2 (en) 2014-03-14 2019-09-03 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
WO2015164580A1 (en) * 2014-04-23 2015-10-29 Auris Medical Ag Methods and compositions for treating and preventing tinnitus
KR101628707B1 (ko) * 2014-05-29 2016-06-10 한남대학교 산학협력단 난청 치료용 약물 전달 시스템 및 이의 제조방법
KR101717585B1 (ko) 2014-12-31 2017-03-20 중앙대학교 산학협력단 약물 방출 조절이 가능한 스캐폴드
JP6716139B2 (ja) * 2015-01-19 2020-07-01 学校法人慶應義塾 内耳性難聴治療薬
HUE056138T2 (hu) 2015-05-18 2022-01-28 Sensorion Azasetron a halláskárosodás kezelésében való felhasználásra
WO2017079505A1 (en) * 2015-11-04 2017-05-11 Research Institute At Nationwide Children's Hospital Rnase7 for treatment of bacterial infection
US10398655B2 (en) 2016-02-18 2019-09-03 Privo Technologies, Inc. Two-stage microparticle-based therapeutic delivery system and method
JP7158723B2 (ja) 2016-04-14 2022-10-24 センソリオン 耳疾患の処置における使用のための（＋）－アザセトロン
US10085097B2 (en) * 2016-10-04 2018-09-25 Starkey Laboratories, Inc. Hearing assistance device incorporating system in package module
US20180179497A1 (en) * 2016-12-20 2018-06-28 Nikita Balashov Katz Artificial immune cell emulating selected properties of granulocytes utilizing Fenton-type reactions
US20180235899A1 (en) 2017-02-17 2018-08-23 Privo Technologies, Inc. Particle-based multi-layer therapeutic delivery device and method
US10478403B1 (en) 2017-05-03 2019-11-19 Privo Technologies, Inc. Intraoperative topically-applied non-implantable rapid release patch
CN108319811B (zh) * 2018-01-15 2021-06-11 深港产学研基地 雷诺丁受体调控心肌细胞中Ca2+波的二维建模方法
US10561736B1 (en) 2019-01-09 2020-02-18 Spiral Therapeutics, Inc. Apoptosis inhibitor formulations for prevention of hearing loss
FR3095755A1 (fr) * 2019-05-10 2020-11-13 Balmes Transplantation Nouveaux médicaments cytoprotecteurs
CA3156698A1 (en) * 2019-10-30 2021-05-06 Alan Foster Otic formulations for drug-induced ototoxicity
WO2021127275A1 (en) * 2019-12-17 2021-06-24 Otonony, Inc. Gsk-3 modulator otic formulations
RU2747401C1 (ru) * 2020-06-22 2021-05-04 Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный университет" Способ получения фармацевтических лекарственных форм на основе сополимеров метилметакрилата
US20240099979A1 (en) * 2021-06-01 2024-03-28 Privo Technologies, Inc. Enhanced two-stage microparticle-based localized therapeutic delivery system
WO2023211226A1 (ko) * 2022-04-27 2023-11-02 주식회사 파이안바이오테크놀로지 미토콘드리아를 유효성분으로 포함하는 난청 또는 이명의 예방 또는 치료용 약학 조성물

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US529251A (en) * 1894-11-13 Cabinet and index-file
US4016254A (en) * 1972-05-19 1977-04-05 Beecham Group Limited Pharmaceutical formulations
US4478822A (en) * 1983-05-16 1984-10-23 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US5292516A (en) * 1990-05-01 1994-03-08 Mediventures, Inc. Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers
CA2040460C (en) * 1990-05-01 1997-06-10 Tacey X. Viegas Drug delivery with thermoreversible gels
IT1251151B (it) * 1991-08-05 1995-05-04 Fidia Spa Materiale spugnoso essenzialmente costituito da acido ialuronico,o suoi derivati
US6531156B1 (en) * 1994-04-15 2003-03-11 Temple University Aqueous solven encapsulation method, apparatus and microcapsules
JP2002515932A (ja) * 1997-04-18 2002-05-28 カリフォルニア インスティチュート オブ テクノロジー 多機能性ポリマー性組織コーティング
SE9704186D0 (sv) * 1997-11-14 1997-11-14 Astra Ab New composition of matter
US6177434B1 (en) * 1997-12-16 2001-01-23 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
US6649621B2 (en) * 1997-12-16 2003-11-18 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
EP1109563A4 (en) * 1998-08-04 2009-07-22 Madash Llp HEAT-SENSITIVE HYDROGELS WITH MODIFIED TERMINATION
US6818018B1 (en) * 1998-08-14 2004-11-16 Incept Llc In situ polymerizable hydrogels
US6740664B2 (en) * 1998-09-30 2004-05-25 Alcon, Inc. Methods for treating otic and ophthalmic infections
JP2002526397A (ja) * 1998-10-05 2002-08-20 ザ ペン ステイト リサーチ ファンデーション レセプター媒介細胞インターナリゼーションを増強するための組成物および方法
US20040082509A1 (en) * 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
KR20010069066A (ko) * 2000-01-12 2001-07-23 이종원 저산소 농도하에서 생존이 가능하도록 하는 동물세포의배양방법
US7029694B2 (en) * 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
US20060269602A1 (en) * 2001-04-13 2006-11-30 Dasch James R Method of modifying the release profile of sustained release compositions
US7001615B1 (en) * 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
JP3776810B2 (ja) * 2002-01-25 2006-05-17 富士写真フイルム株式会社 感熱記録材料及び感熱記録方法
US20030229333A1 (en) * 2002-02-22 2003-12-11 Control Delivery Systems, Inc. Methods for treating otic disorders
AU2003286792A1 (en) * 2002-10-29 2004-05-25 Oregon Health And Science University Fludrocortisone treatment for hearing loss
US7220431B2 (en) * 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
US7842791B2 (en) * 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions
AR045062A1 (es) * 2003-07-18 2005-10-12 Santarus Inc Formulaciones farmaceuticas para inhibir la secrecion de acido y metodos para preparar y utilizarlas
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2005009287A2 (en) * 2003-07-21 2005-02-03 University Of Maryland, Baltimore Drug delivery to the inner ear and methods of using same
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
WO2005046438A2 (en) * 2003-11-06 2005-05-26 Pluromed, Inc. Internal clamp for surgical procedures
US20060063802A1 (en) * 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US8268866B2 (en) * 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
ES2313368T3 (es) * 2004-06-23 2009-03-01 Sirion Therapeutics, Inc. Metodos y composiciones para el tratamiento de afecciones oftalmicas con derivados de retinilo.
US20060046970A1 (en) * 2004-08-31 2006-03-02 Insite Vision Incorporated Topical otic compositions and methods of topical treatment of prevention of otic infections
WO2006024966A2 (en) * 2004-09-02 2006-03-09 Angela Cruz Three-dimensional self assembly in suspension of adherent cells
JP2008520585A (ja) * 2004-11-16 2008-06-19 ルネサンス ハーブス インコーポレイテッド ガルシニア・マンゴスタナｌ植物から導く薬剤及び治療組成物
EP1861161A4 (en) * 2005-01-24 2012-05-16 Neurosystec Corp APPARATUS AND METHOD FOR DISPENSING THERAPEUTIC AND / OR OTHER AGENTS IN THE INTERNAL EAR AND OTHER FABRICS
ES2524994T3 (es) * 2005-09-28 2014-12-16 Auris Medical Ag Composiciones farmacéuticas para el tratamiento de trastornos del oído interno.
US20070178051A1 (en) * 2006-01-27 2007-08-02 Elan Pharma International, Ltd. Sterilized nanoparticulate glucocorticosteroid formulations
EP1844653B1 (en) * 2006-03-30 2017-07-26 GAT Microencapsulation GmbH Novel agrochemical formulations containing microcapsules
US20080051319A1 (en) * 2006-08-22 2008-02-28 Children's Medical Center Corporation Inhibiting JNK Signaling Promotes CNS Axon Regeneration
US20080103118A1 (en) * 2006-10-27 2008-05-01 Iomedix Development International Srl Composition for improving blood cholesterol levels
US8030297B2 (en) * 2008-05-14 2011-10-04 Otonomy, Inc. Controlled release corticosteroid compositions and methods for the treatment of OTIC disorders
US8822410B2 (en) * 2008-05-19 2014-09-02 Children's Medical Center Corporation Tympanic membrane permeating ear drops and uses thereof
US8648119B2 (en) * 2008-05-23 2014-02-11 Otonomy, Inc. Controlled release immunomodulator compositions and methods for the treatment of otic disorders
US8846770B2 (en) * 2008-06-18 2014-09-30 Otonomy, Inc. Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders
US8349353B2 (en) * 2008-06-27 2013-01-08 Otonomy, Inc. Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders
WO2010011466A2 (en) * 2008-06-27 2010-01-28 Otonomy, Inc. Controlled-release cns modulating compositions and methods for the treatment of otic disorders
US8399018B2 (en) * 2008-07-21 2013-03-19 Otonomy, Inc. Controlled release ion channel modulator compositions and methods for the treatment of otic disorders
US8784870B2 (en) * 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
US8496957B2 (en) * 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US8318817B2 (en) * 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders

Also Published As

Publication number Publication date
WO2010008995A2 (en) 2010-01-21
AU2009271129B2 (en) 2013-10-10
IL210553A0 (en) 2011-03-31
AU2009271129A1 (en) 2010-01-21
CN102099013A (zh) 2011-06-15
RU2011105257A (ru) 2012-08-20
WO2010008995A3 (en) 2010-04-01
EP2296632A4 (en) 2014-11-12
JP5491502B2 (ja) 2014-05-14
CA2730847A1 (en) 2010-01-21
US20100016218A1 (en) 2010-01-21
EP2296632A2 (en) 2011-03-23
KR101390607B1 (ko) 2014-05-19
ZA201008861B (en) 2011-09-28
RU2493828C2 (ru) 2013-09-27
JP2011528036A (ja) 2011-11-10
MX2011000545A (es) 2011-02-24
KR20110025867A (ko) 2011-03-11
US20190298799A1 (en) 2019-10-03
US20160199446A1 (en) 2016-07-14
IL266471A (en) 2019-07-31

Similar Documents

Publication Publication Date Title
BRPI0915770A2 (pt) composição de modulação de apoptose de liberação controlada e métodos para o tratamento de distúrbios ótológicos
BRPI0916323A2 (pt) composições antimicrobianas de liberação controlada e métodos para o tratamento de distúrbios do ouvido
BRPI0919920A2 (pt) compostos para tratamento de doenças e desordens oftálmicas
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
BRPI0918476A2 (pt) dímeros de pirrolobenzodiazepina assimétricos para o tratamento de doenças proliferativas
BRPI0810082A2 (pt) 3-imidazolil-indóis para o tratamento de doenças proliferativas
BRPI0918527A2 (pt) compostos para o tratamento de disturbios do cns
BRPI0819678A2 (pt) método para tratar cmt e distúrbios relacionados
HK1175716A1 (en) Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders 13--2--1-
BRPI0810946A2 (pt) Método para tratamento de hérnia de disco
BRPI1006979A2 (pt) métodos para tratar infartos agudos do miocárdio e distúrbios associados
BRPI0919238A2 (pt) métodos e composições para o tratamento de câncer
GB2467710B (en) Methods for treating social disorders
BRPI0908715A2 (pt) métodos para tratamento da psoríase
EP2323681A4 (en) METHODS OF TREATING VIRAL CONDITIONS
BRPI0909164A2 (pt) método e composições para o tratamento de câncer
BRPI0816712A2 (pt) terapia de intervalo para o tratamento de tinnitus
EP2142206A4 (en) METHOD FOR THE TREATMENT OF ISCHEMIC ILLNESSES
ZA201002167B (en) Treatment regime for proliferative disorders
BR112012006437A2 (pt) composições e métodos para tratamento do diabetes e outros distúrbios
BRPI1007529A2 (pt) métodos para regeneração de tecido pancreático
BRPI0920728A2 (pt) Composição estabilizada para tratamento de psoríase
BRPI0910998A2 (pt) composição para tratamento de acne e método para tratar acne
BRPI0918508A2 (pt) orto-aminoanilidas para o tratamento de câncer
BRPI0812034A2 (pt) Combinações de neramexano para o tratamento de distúrbios neurodegenerativos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.